Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for Prevention of Altitude-related Illness in COPD
NCT04913389Phase 3Unknown
- Sponsor
- University of Zurich
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Altitude sickness (AMS) and hypoxia comparing Acetazolamide with Placebo (2 arms). Primary endpoint: Incidence of altitude-related adverse health effects. Status: unknown.
02
Drugs
acetazolamide
03
Conditions
Altitude sickness (AMS)hypoxia
Beyond the preview
Go deeper on NCT04913389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913389.